146139-53-9

Basic information

• Product Name: Ethyl 2-(1H-Pyrazol-1-yl)benzoate
• Synonyms: Ethyl 2-(1H-Pyrazol-1-yl)benzoate;Ethyl 2-(1-Pyrazolyl)benzoate;ethyl 2-pyrazol-1-ylbenzoate
• CAS NO: 146139-53-9
• Molecular Formula: C₁₂H₁₂N₂O₂
• Molecular Weight: 216.23588
• Mol File: 146139-53-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 343.3°C at 760 mmHg
• Flash Point: 161.4°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 7.11E-05mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: Ethyl 2-(1H-Pyrazol-1-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(1H-Pyrazol-1-yl)benzoate(146139-53-9)
• EPA Substance Registry System: Ethyl 2-(1H-Pyrazol-1-yl)benzoate(146139-53-9)

Safety Data

• Statements: 20/21/22
• Safety Statements: 24/25-36/37
• Hazardous Substances Data: 146139-53-9(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow liquid

InChI:InChI=1/C12H12N2O2/c1-2-16-12(15)10-6-3-4-7-11(10)14-9-5-8-13-14/h3-9H,2H2,1H3

Upstream product

• 55317-53-8 2-(1H-pyrazol-1-yl)benzoic acid 
• 64-17-5 ethanol 
• 288-13-1 NH-pyrazole 
• 443-26-5 2-fluoro-benzoic acid ethyl ester 
• 1829-28-3 ethyl 2-iodobenzoate 

Downstream Products

• 55317-53-8 2-(1H-pyrazol-1-yl)benzoic acid 
• 1126-00-7 1-phenylpyrazole 

Relevant articles and documents

Nickel-catalyzed reductive defunctionalization of esters in the absence of an external reductant: Activation of C-O bonds

The nickel-catalyzed reductive cleavage of esters in the absence of an external reductant, which involves the cleavage of an inert acyl C-O bond in O-Alkyl esters is reported. Various groups, such as N-containing heterocycles, esters, amides, and even arene rings can function as a directing group.

2, 3, 4, 5-TETRAHYDRO-1H-[1, 4] BENZODIAZEPINE-3-HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS

Compounds having formula (1) are useful in treating disease conditions mediated by matrix metalloproteinases and TACE, such as tumor growth, osteoarthritis, rheumatoid arthritis and degenerative cartilage loss.

2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids

Compounds are provided having the following formula: wherein R, R1, R2, R3, and R4 are defined in the specification, which have matrix metalloproteinase inhibiting activity.